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Background. Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic
ﬁbrosis (CF) and exocrine pancreatic insuﬃciency (PI). Aim.T oe v a l u a t ee ﬃcacy and safety of a new formulation of pancrelipase
(Ultrase MT20) in patients with CF and PI. Coeﬃcients of fat absorption (CFA%) and nitrogen absorption (CNA%) were the
main eﬃcacy parameters. Safety was evaluated by monitoring laboratory analyses, adverse events (AEs), and overall signs and
symptoms. Methods. Patients (n = 31) were randomized in a crossover design comparing this pancrelipase with placebo during 2
inpatient evaluation periods (6-7 days each). Fat and protein/nitrogen ingestion and excretion were measured from food diaries
and 72-hour stool collections. CFA% and CNA% were calculated for each period and compared. Results. Twenty-four patients
provided analyzable data. This pancrelipase increased mean CFA% and CNA% (+34.7% and +25.7%, resp., P<. 0001 for both),
reducedstoolfrequency,andimprovedstoolconsistencycomparedwithplacebo.Placebo-treatedpatientsreportedmoreAEs,with
gastrointestinal symptoms being the most frequently reported AE. Conclusions. This pancrelipase is a safe and eﬀective treatment
for malabsorption associated with exocrine PI in patients with CF.
1.Introduction
Exocrine pancreatic insuﬃciency (PI) is the most commonly
reported gastrointestinal (GI) complication in patients with
cystic ﬁbrosis (CF), aﬀecting approximately 90% of the
CF population [1, 2]. PI results from obstruction of the
pancreatic duct and leads to failure of pancreatic enzyme
secretion (lipases, amylases, and proteases) [1–3]. If left
untreated, PI results in the absorption of only 50% to 60%
of dietary fats and proteins [4]. This malabsorption leads
to depriving the body of energy it requires to maintain and
promote growth. As a result, infants can experience failure2 Gastroenterology Research and Practice
to thrive, children and adolescents can have poor weight
gain and/or growth failure, and adults can lose weight. In
addition, the majority of patients with CF and PI have fat-
soluble vitamin and essential fatty acid deﬁciencies [2, 5].
Evidence suggests that poor nutritional status may impair
pulmonary function and may shorten the life expectancy
of patients with CF [6, 7]. Other signs and symptoms of
PI include abdominal distention and discomfort, ﬂatulence,
and frequent bulky, greasy, and foul-smelling stools, all of
which may have a negative impact on the quality of life of
aﬀected patients.
While pancreatic enzyme replacement therapy (PERT)
doesnotcompletelynormalizePI,itdoesresultinanincrease
in fat absorption above 85% in most patients with CF, and
the advent of this therapy has contributed to a signiﬁcant
improvement in the outcomes of these patients [7–11].
Additionally, PERT allows patients with CF to eat a normal
diet high in fat, absorb necessary nutrients, avoid many of
the disabling GI symptoms associated with PI, and grow and
develop more appropriately [1].
All currently marketed pancreatic enzyme products used
to manage PI in patients with CF are a mixture of porcine-
derived pancrelipase composed of varying amounts of
lipase, amylase, and protease contained in an enteric-coated
minitablet or microsphere [10, 12]. The enteric coating pro-
tects the enzymes from gastric acid-mediated degradation
and is designed to dissolve at a pH above 5 to release proper
amounts of enzymes in the upper small intestine where they
digest fats, proteins, and carbohydrates [13]. Enteric-coated
formulations have largely replaced nonenteric preparations
for addressing PI in CF.
ThepancrelipaseUltraseMT(AxcanPharmaInc.,Mont-
Saint-Hilaire, QC, Canada) consists of orally administered
capsules containing enteric-coated minitablets of porcine-
derived pancrelipase containing lipases, amylases, and pro-
teases and is indicated for the treatment of patients with
PI secondary to CF or other conditions [14]. The eﬃcacy
and safety of a former formulation of this pancrelipase
(minitablets coated with Eudragit) has been demonstrated
in 2 randomized, placebo-controlled studies performed
in patients with CF and PI aged 7 years and older
[8]. This pancrelipase was associated with a clinically
signiﬁcant increase (P<. 0001) in the coeﬃcient of
fat absorption (CFA%) and nitrogen absorption (CNA%)
compared with placebo. To increase the stability of the
pancrelipase minitablets, the Eudragit coating was replaced
by hydroxypropyl-methylcellulose phthalate-55 (HP55) in
2004, but the active pharmaceutical ingredients remain iden-
tical. The eﬃcacy and safety of the HP55-coated formulation
of this pancrelipase was assessed in this new randomized,
placebo-controlled study in pediatric, adolescent, and adult
patients with CF and PI.
2.MaterialsandMethods
2.1. Patients. Eligible patients included males and females
aged 7 years and older with a conﬁrmed diagnosis of CF and
PI,thelatterwasconﬁrmedbyfecalelastase(FE-1)<100μg/g
of stool at the screening visit. With the exception of the
underlying signs and symptoms associated with CF and PI,
patients were to be clinically stable at study entry (based
on medical and medication history, physical examination,
and laboratory testing). Patients were taking optimal doses
of a pancreatic enzyme product and were required to have
adequate nutritional status (body mass index [BMI] ≥ 5th
percentile for patients aged 7 to 20 years; and for those aged
>20 years, BMI ≥16.0kg/m2 for females and ≥16.5kg/m2
for males). Patients were to be able to swallow capsules of
study drug and to eat a high-fat diet (2 grams of fat/kg of
body weight/day ± 15%). Women of childbearing potential
were to have practiced an acceptable method of birth control
for at least 1 month prior to study entry and to continue
birth control for the duration of the study. Patients who used
proton pump inhibitor (PPI) or histamine-2 blockers were
allowed to continue their therapy during the study.
Exclusion criteria included known contraindication or
hypersensitivity to Ultrase MT or to porcine proteins, allergy
to the FD&C Blue no. 2 dye indicator (stool marker), use of
narcotics, use of bowel stimulants or laxatives on a regular
basis, use of any prohibited medication that could aﬀect
intestinal motility or absorption, history of bowel resection,
or history of portal hypertension. Patients with acute pul-
monaryinfection,acutepancreatitis,exacerbationofchronic
pancreatitis, celiac disease, gastrointestinal dysmotility dis-
orders, chronic or severe abdominal pain, poorly controlled
diabetes, or with any conditions known to increase fecal fat
loss were ineligible for the study. Patients with a current
diagnosis or history of complete distal intestinal obstruction
syndrome (DIOS) as deﬁned by recent criteria [15] within
the past 6 months or with 2 or more episodes within 1 year
were also ineligible.
The study was conducted in accordance with the
principles of Good Clinical Practice as identiﬁed by the
International Conference on Harmonization and applicable
national regulations [16]. The Institutional Review Board at
each study site reviewed and approved the study protocol,
consent and assent forms, and all related study documents.
Written informed consent was obtained from all patients
or their parents/legal representatives, and assent was also
obtained from minors.
2.2. Study Design. This was a randomized, double-blind,
crossover study that compared the eﬃcacy and safety of this
new formulation of pancrelipase (20,000 IU lipase/capsule)
with that of placebo in the treatment of malabsorption
in patients with CF and PI. The study was conducted at 8
centers within the United States between November 2006
and March 2007, and extensive and ongoing collaboration
was maintained with the Cystic Fibrosis Foundation—
Therapeutics Development Network Coordinating Center.
The duration of the study was from 41 to 49 days and
included a screening phase of up to 11 days, a comparison
p h a s eo fu pt o2 8d a y s ,a n daf o l l o w - u pv i s i t( Figure 1).
At the screening visit, patient eligibility was evaluated by
detailed medical history, physical examination, and clinical
laboratory assessments (hematology, chemistry, urinalysis,Gastroenterology Research and Practice 3
Comparison phase
Screening
Evaluation 1 Evaluation 2
(6 to 7 days) (6 to 7 days)
Up to 11 days Stabilization 1
(4 days) Follow-up visit
(7 to 10 days later)
Break
(3 to 6 days) +
stabilization 2
(4 days)
Randomization
Open-label pancrelipase
Double-blind study medication (pancrelipase, crossover to placebo)
Double-blind study medication (placebo, crossover to pancrelipase)
End of study
Figure 1: Schema of study design with a screening phase followed by a randomized crossover comparison phase that included 2 stabilization
periods, a break period and 2 evaluation periods.
and serum pregnancy test for females of childbearing
potential analyzed by Mayo Central Laboratory for Clin-
ical Trials, Rochester, MN, USA, and FE-1 [by ScheBo
test kit] analyzed by Genova Diagnostics, Asheville, NC,
USA).
A registered dietician at each study site developed a high-
fat diet customized for each patient, which contained 2g
fat (±15%)/kg body weight. This high-fat diet was to be
introduced on the ﬁrst day of the comparison phase and was
continued throughout the course of the study, except during
the break period. Patients received open-label pancrelipase
during the entire screening phase of 11 days.
The screening phase was followed by the comparison
phase, which consisted of 2 evaluation periods lasting 6 to
7 days each, separated by a break period. An outpatient
stabilization period of 4 days on open-label pancrelipase
precededeachinpatientevaluationperiodtoestablishsimilar
baseline conditions.
Duringstabilizationperiods1and2,patientsmaintained
their individualized high-fat diets and recorded the type
and quantity of each food and liquid ingested for further
assessment of fat, protein, and carbohydrate in their diet.
The dose of pancrelipase (number of capsules) was adjusted
and stabilized according to the clinician’s observations and
the patient’s symptoms during stabilization period 1 to
accountfortheincreasedamountofdietaryfat.Patientswere
considered stable when they had 3 bowel movements/day or
fewer, or when additional capsules of pancrelipase resulted
in no further reduction in stool frequency. The stabilized
dose (ﬁxed number of capsules) was determined by the
investigator at the end of stabilization period 1 and did
not exceed 2500 IU of lipase/kg per meal or snack, as
recommended in the CF Foundation Consensus Report
on Nutrition for pediatric patients [17]. The stabilized
dose was the dose of study drug dispensed during both
inpatient evaluation periods as well as stabilization period
2.
Patientswereadmitted twicetoageneralclinicalresearch
center (GCRC) for 6 to 7 days to complete the evaluation
periods. Randomization occurred on day 1 of evaluation
period 1, and patients were administered the stabilized dose
of the double-blinded study drug (pancrelipase or matching
placebo) for the duration of the evaluation period. After
a 3- to 6-day break and the second 4-day stabilization
period, patients were readmitted to the GCRC to complete
evaluation period 2 and crossed over to the opposite
treatment received during evaluation period 1.
Each patient’s high-fat diet was carefully recorded by
study personnel during both inpatient evaluation periods for
further assessment of fat, protein, and carbohydrate. Study
drug was administered under supervision with each meal
or snack and recorded daily during both evaluation periods.
The compliance to study drug was calculated by comparing
the daily intake of capsules of study drug during inpatient
evaluation periods with the stabilized dose established at
stabilization period 1. Stools were collected as described
below, and their frequency and characteristics were recorded
in a diary during the collection period by study personnel.
Patients had a physical examination including assessment
of vital signs and laboratory evaluation at the end of each
evaluation period. A follow-up visit was scheduled 7 to 10
days following discharge from evaluation period 2 or early
discontinuation, for any patient who took at least 1 dose of
study drug. Treatment-emergent adverse events (AEs) were4 Gastroenterology Research and Practice
assessed and recorded throughout the study using MedDRA
codiﬁcation, version 9.0 [18].
2.3. Stool Collections. The stool collections were performed
in the GCRC and started on day 3 of each evaluation period.
Patients were given 2 capsules containing 250 mg FD&C blue
no. 2 dye (a stool marker) with their breakfast to mark the
start of the stool collection. A second and similar dose of
marker was administered 72 hours later (day 6) to mark
the end of the stool collection, or exceptionally 96 hours
later (day 7) if the ﬁrst blue marker did not appear in
the stool within 36 hours of administration. The ﬁrst blue-
tinted stool that appeared after administration of the ﬁrst
marker was not saved, but all stools (blue tinted or not) from
subsequent bowel movements were collected and saved, up
to and including the appearance of the ﬁrst blue-tinted stool
from the second marker administered on day 6 or 7. Stool
samples from each evaluation period were sent to a central
laboratoryforanalysisofcumulativefatandnitrogencontent
(MayoCentralLaboratoryforClinicalTrials,Rochester,MN,
USA). The diaries completed during stool collection by
study personnel from all sites were analyzed by a registered
dietician acting as a central reader, using a nutrition analysis
software program (ESHA Food Processor Software, Salem,
OR,USA)forfatandproteincontent.TheCFA%andCNA%
were calculated for each patient using the fat and nitrogen
content of the stool and the fat and protein (converted in
nitrogen equivalent) content of the food.
2.4. Statistical Analysis. Theprimary(CFA%)andsecondary
(CNA%) eﬃcacy parameters of each treatment (pancreli-
pase and placebo) were compared using a semiparametric
approach (Iman Conover). The entire set of observations
was rank transformed, and a mixed model that included
sequence, period, and treatment group as ﬁxed eﬀects and
patient identiﬁcation as a random eﬀect was applied to
the transformed data [19, 20]. Mean values were reported
with their standard deviation (SD), and 2-sided statistical
comparisons were carried out at the 0.05 signiﬁcance level.
The primary model was a main-eﬀect model without
interaction terms conducted in the primary eﬃcacy patient
population, which was deﬁned to include all randomized
subjects (intent-to-treat [ITT] population). Based on the
results of a similar study and assuming a 2-sided α-error
probability of 0.05 and a power of 80%, it was determined
that a sample size of 24 evaluable patients was needed to be
able to detect a minimum diﬀerence in CFA% of 18 with an
SD of 30 between the 2 treatment groups.
The per-protocol population included all patients who
completedbothevaluationperiodswithoutanymajorproto-
col violations and who provided eﬃcacy data. The modiﬁed
ITT (mITT) population consisted of all randomized patients
whocompletedthe2treatmentperiodsandprovidedeﬃcacy
data (evaluable patients). All patients who received at least 1
dose of study drug, including open-label pancrelipase during
the screening phase, were included in the safety population.
Only descriptive statistics were performed on the safety data.
Table 1: Baseline characteristics of study patients.
Safety population mITT population
N = 31 N = 24
Age (years) 19.6 ± 6.61 9 .1 ± 5.9
Gender, n (%)
Male 20 (64.5) 15 (62.5)
Female 11 (35.5) 9 (37.5)
Race, n (%)
Caucasian 29 (93.5) 23 (95.8)
Black 2 (6.5) 1 (4.2)
Weight (kg) 55.6 ± 11.65 5 .0 ± 9.6
BMI (kg/m2)2 0 .4 ± 2.22 0 .1 ± 1.9
Fecal elastase-1, n (%)
<15 (μg/g of stool) 30 (96.8) 23 (95.8)
=34 (μg/g of stool) 1 (3.2) 1 (4.2)
Values are mean ± 1 standard deviation, unless otherwise noted. BMI: body
mass index; mITT: modiﬁed Intent-To-Treat (patients completing both
treatment periods).
3. Results
3.1. Patient Disposition and Characteristics. Thirty-seven
patients were screened, and 32 were enrolled in the com-
parison phase of the study. One enrolled patient started
stabilization period 1 but withdrew consent and was not
randomized to study treatment. The 31 randomized patients
(ITT/safety population) ranged in age from 8 to 37 years
with a mean ± SD of 19.6 ± 6.6 years. Five of the 31
patients discontinued the study prematurely: 1 for protocol
deviation, 1 withdrew consent, and 3 for AEs. Twenty-
six patients completed both study periods, but incomplete
food recordings prevented calculation of CFA% and CNA%
for 2 patients. Twenty-four patients provided complete
eﬃcacy data and comprised the mITT population. All 31
randomized patients were included in the safety analysis. All
patients had severe pancreatic insuﬃciency as demonstrated
by FE-1< 100μg/g of stool. In the eﬃcacy population, 62.5%
of patients (n = 15) were using a PPI or histamine-2 blocker
during the study, while 37.5% (9 patients) did not. Baseline
characteristics of these patient populations are summarized
in Table 1.
3.2. Diet, Treatment Exposure, and Compliance. The mean
total daily dietary fat and protein intakes during the 2
double-blind evaluation periods were highly comparable in
the mITT population (Table 2). Patients in the mITT popu-
lation received a mean lipase dose of 6270 ± 2091IU/kg/day
while patients in the safety population received a mean lipase
dose of 6062 ± 2049IU/kg/day, with a range of 2830 to
10,619IU lipase/kg/day. The mean lipase dose administered
per meal or snack was 1262 ± 511IU/kg with a range of 545
to 2292IU/kg/meal or snack. For safety reasons, a consensus
conference on the use of pancreatic enzyme supplements
recommended that the daily dose of pancreatic enzymes
for most patients should remain below 2500 U of lipase/kg
per meal (10,000U/kg/day) [21]. In the safety population,Gastroenterology Research and Practice 5
Table 2: Dietary intake and absorption in the mITT population
(n = 24).
Treatment Treatment
Pancrelipase Placebo Diﬀerence∗ P-value
Fat intake
(g/day)
116.9 ±21.9
(77–168)
119.8 ±29.8
(69–219) .40
Protein
intake
(g/day)
119.5 ±39.6
(40–216)
120.0 ±36.3
(40–188) .86
CFA (%) 88.6 ±5.0
(77–97)
53.9 ±25.5
(14–97)
34.7 ±25.0
(−7–75) <. 001
CNA (%) 84.0 ±7.4
(62–95)
58.3 ±20.6
(30–96)
25.7 ±17.7
(−9–52) <. 001
All values expressed as mean ± 1 standard deviation (range).
∗Mean treatment diﬀerence determined from within-patient diﬀerences.
CFA: coeﬃcient of fat absorption; CAN: coeﬃcient of nitrogen absorption;
mITT: modiﬁed Intent-To-Treat (patients completing both treatment
periods).
compliance in taking the study drug was high and consistent
in the 2 evaluation periods. Average compliance was 98.3 ±
9.2% for the pancrelipase treatment period and 97.4 ± 7.6%
for the placebo period.
3.3. Eﬃcacy Assessments. Patients treated with pancrelipase
had a signiﬁcantly higher mean CFA% (88.6 ± 5.0%) than
patients treated with placebo (53.9 ± 25.5%; P<. 0001).
The mean diﬀerence between treatment groups was 34.7 ±
25.0% (Table 2). Seventy-six percent of patients achieved a
CFA% > 85% during pancrelipase treatment compared
with 19% of placebo-treated patients, and nearly 50% of
all patients achieved a CFA% >90% during pancrelipase
treatment. The absorption of proteins measured by CNA%
showed similar results with a mean CNA% signiﬁcantly
greater (P<. 0001) for the pancrelipase group (84.0 ± 7.4%)
than for the placebo group (58.3 ± 20.6%) with a mean
diﬀerenceof25.7 ±17.7%betweentreatments(Table 2).The
period and sequence eﬀe c t sf o rb o t hC F A %a n dC N A %w e r e
not statistically signiﬁcant (data not shown).
Patients treated with pancrelipase had 1.7 ± 0.6 bowel
movements per day with 73.4 ± 27.6% described as being
of normal stool consistency, compared with 2.9 ± 1.1 bowel
movements per day with 31.6 ± 27.9% being of normal
stool consistency during the placebo period (no statistical
comparison performed).
3.4. Safety Assessments. Of the patients who received at
least 1 dose of study drug, 17 (54.8%) and 27 (87.1%)
reported treatment-emergent AEs during the pancrelipase
and placebo periods, respectively. A total of 33 and 109
AEs were reported during the pancrelipase and placebo
periods, respectively. No patient reported severe AEs while
receiving pancrelipase compared with 5 patients (16.1%)
receiving placebo who reported 7 severe AEs. Except for 1
severe AE (abdominal pain) judged as probably related to the
placebo treatment by the investigator, the 6 other severe AEs
were judged not related to treatment. There were 6 patients
(19.1%) who reported at least 1 treatment-related AE on
pancrelipase compared with 18 patients (58.1%) receiving
placebo. The most frequently reported AEs were GI and
consistent with CF, with fewer patients experiencing AEs
of any type during treatment with pancrelipase than with
placebo. No clinically signiﬁcant eﬀects of treatment were
observed in any of the safety laboratory assessments, physical
examinations, or vital signs.
4. Discussion
The primary end point of this study was the comparison of
CFA%, calculated from all fat excreted in the stools over 72
hours and from concomitant fat intake, between the new
formulation of pancrelipase and placebo. This measure is
currently considered the gold standard to assess the eﬃcacy
of PERT in patients with CF and PI. The crossover design
of this study, which uses patients as their own matched
controls, allowed treatment diﬀerences between pancrelipase
and placebo to be estimated with greater precision [22].
The baseline conditions were carefully reestablished before
each evaluation period by the preceding 4-day stabilization
periods and controlled for carryover eﬀect of one treatment
period to the other.
The treatment with pancrelipase signiﬁcantly improved
both fat (88.6 versus 53.9%) and nitrogen (84.0 versus
58.3%) absorption compared with placebo (P<. 0001). The
results are very similar to those obtained in a previous study
performed with the former formulation of pancrelipase,
where coeﬃcients of fat and nitrogen absorption were 87.3
and 88.6%, respectively [8]. This suggests that the change
in enteric coating did not aﬀect the eﬃcacy of this new
formulation of pancrelipase.
In the current study, a large majority of the patients
reached a CFA% above 85% and almost half reached ≥ 90%.
An increase in CFA% to ≥ 85% is considered a meaningful,
signiﬁcant improvement that approaches normal fat absorp-
tion [4, 23]. Other beneﬁcial clinical aspects of pancrelipase
treatment were observed in this study, including reduction
in abdominal pain and frequency of stools, and a report
of more normal stool consistency. Although the treatment
period in this study was short, this pancrelipase seemed to be
well tolerated, and no safety concerns were raised with this
treatment in the population evaluated.
Excessive intake of exogenous pancreatic enzymes has
been associated with the development of ﬁbrosing colonopa-
thy in patients with CF [24, 25]. Guidelines initially pub-
lished in 1995 and updated in 2002 recommended no greater
than 2500IU of lipase per kg/meal, with a maximum daily
dose of 10,000IU of lipase per kg [17, 21]. In the current
study, enzyme intake was considerably lower than these dose
limits and well below doses associated with the development
of colonic strictures.
5. Conclusion
Ultrase MT has been in clinical use for more than 10
years before the 2004 change in the enteric coating of the6 Gastroenterology Research and Practice
minitablets. The current study provides substantial evidence
that this new formulation of this pancrelipase (HP55-
coated) is both a clinically eﬀective and safe pancreatic
enzyme replacement therapy requiring relatively low doses
for treating PI associated with CF.
Acknowledgments
This work was supported by Axcan Pharma Inc. The authors
express their gratitude to the participating CF patients; to
the research coordinators at the study sites: Colette Bucur,
Kristyn Packer, Mary Teresi, Catherine Dudderar, Diane
Kitch, Sue Collin, Teri Crumb, and Dawn Kruse; to the
dieticians, pharmacists, and staﬀ of the GCRCs at each
study site; to the Cystic Fibrosis Therapeutics Development
Network (CF-TDN) for its input on the protocol design
and research services; to Dr John L. Colombo, the chair
of the CF Data Monitoring Committee of the Data Safety
Monitoring Board; to Jonathan M. Wert, MD, of BlueSpark
Healthcare Communications LLC for assistance with the
preparation of this paper for submission. M. W. Konstan,
MD discloses a consulting relationship with Axcan Pharma
Inc., Digestive Care Inc., and Solvay Pharmaceuticals. S. D.
Strausbaugh, MD, S. Z. Nasr, MD, and K. Moﬀett, MD
disclose a consulting relationship with Axcan Pharma Inc.
J. Sp´ enard, PhD, and J. Grondin, MSc, are both full-time
employees of Axcan Pharma Inc. This study was supported
by National Institutes of Health (NIH) GCRC National
Center for Research Resources (NCRR) Grants nos. M01-
RR00080 (Drs. Konstan and Strausbaugh), RR00059 (Dr.
Ahrens), RR000042 (Dr. Nasr), RR000064 (Dr. Liou), and
RR010732(Dr.Graﬀ).Thecontentissolelytheresponsibility
of the authors and does not represent the views of the NCRR
or the NIH.
References
[ 1 ]S .S .B a k e r ,D .B o r o w i t z ,a n dR .D .B a k e r ,“ P a n c r e a t i c
exocrine function in patients with cystic ﬁbrosis,” Current
Gastroenterology Reports, vol. 7, no. 3, pp. 227–233, 2005.
[2] P. B. Davis, M. Drumm, and M. W. Konstan, “Cystic ﬁbrosis,”
American Journal of Respiratory and Critical Care Medicine,
vol. 154, no. 5, pp. 1229–1256, 1996.
[3] D. Borowitz, “Update on the evaluation of pancreatic exocrine
status in cystic ﬁbrosis,” Current Opinion in Pulmonary
Medicine, vol. 11, no. 6, pp. 524–527, 2005.
[4] D. Borowitz, M. W. Konstan, A. O’Rourke, M. Cohen,
L. Hendeles, and F. T. Murray, “Coeﬃcients of fat and
nitrogen absorption in healthy subjects and individuals with
cystic ﬁbrosis,” The Journal of Pediatric Pharmacology and
Therapeutics, vol. 12, pp. 47–52, 2007.
[5] B. W. Ramsey, P. M. Farrell, and P. Pencharz, “Nutritional
assessment and management in cystic ﬁbrosis: a consensus
report,” American Journal of Clinical Nutrition,v o l .5 5 ,n o .1 ,
pp. 108–116, 1992.
[6] C. E. Milla, “Nutrition and lung disease in cystic ﬁbrosis,”
Clinics in Chest Medicine, vol. 28, no. 2, pp. 319–330, 2007.
[7] M.W .K o nstan,S.M.B u tle r ,M.E.B .W ohletal.,“ G r o wthand
nutritional indexes in early life predict pulmonary function in
cystic ﬁbrosis,” Journal of Pediatrics, vol. 142, no. 6, pp. 624–
630, 2003.
[ 8 ]M .W .K o n s t a n ,R .C .S t e r n ,J .R .T r o u te ta l . ,“ U l t r a s eM T 1 2
and ultrase MT20 in the treatment of exocrine pancreatic
insuﬃciency in cystic ﬁbrosis: safety and eﬃcacy,” Alimentary
Pharmacology and Therapeutics, vol. 20, no. 11-12, pp. 1365–
1371, 2004.
[9] M. Kraisinger, G. Hochhaus, A. Stecenko, E. Bowser, and
L. Hendeles, “Clinical pharmacology of pancreatic enzymes
in patients with cystic ﬁbrosis and in vitro performance of
microencapsulated formulations,” Journal of Clinical Pharma-
cology, vol. 34, no. 2, pp. 158–166, 1994.
[10] E. A. Mitchell, C. Quested, R. E. Marks, R. E. Pinnock,
and R. B. Elliott, “Comparative trial of Viokase, pancreatin
and Pancreas pancrelipase (enteric coated beads) in the
treatment of malabsorption in cystic ﬁbrosis,” Australian
Paediatric Journal, vol. 18, no. 2, pp. 114–117, 1982.
[11] W. A. Daniel, “Fibrocystic disease of the pancreas,” American
Journal of Diseases of Children, vol. 64, pp. 33–42, 1942.
[12] E.Lebenthal,D.D.K.Rolston,andD.S.HolsclawJr.,“Enzyme
therapy for pancreatic insuﬃciency: present status and future
needs,” Pancreas, vol. 9, no. 1, pp. 1–12, 1994.
[13] R. J. Kuhn, “In vitro comparison of physical parameters,
enzyme activity, acid resistance, and pH dissolution character-
isticsofenteric-coatedpancreaticenzymepreparations:impli-
cationsforclinicalvariabilityandpharmacysubstitution,”The
JournalofPediatricPharmacologyandTherapeutics,vol.12,no.
2, pp. 115–128, 2007.
[14] Ultrase MT, (pancrelipase) capsules [Package insert].
Bridgewater, N.J. Axcan Pharma Inc., January 2010, http://
www.axcan.com/pdf/ultrase.pdf.
[15] R. H. Houwen, H. P. van der Doef, I. Sermet et al., “Deﬁning
DIOS and constipation in cystic ﬁbrosis with a multicentre
study on the incidence, characteristics, and treatment of
DIOS,”JournalofPediatricGastroenterologyandNutrition,vol.
50, no. 1, pp. 38–42, 2010.
[16] “Good Clinical Practice: Consolidated Guideline,” Interna-
tional Conference on Harmonization (ICH), Report no.
E6(R1), 53 pages, May 1996.
[17] D. Borowitz, R. D. Baker, and V. Stallings, “Consensus report
on nutrition for pediatric patients with cystic ﬁbrosis,” Journal
of Pediatric Gastroenterology and Nutrition,v o l .3 5 ,n o .3 ,p p .
246–259, 2002.
[18] “Clinical Safety Data Management: Deﬁnitions and Standards
for Expedited Reporting,” Food and Drug Administration,
International Conference on Harmonisation, Washington,
DC, USA, Report no. 60, 11284 pages, March 1995.
[19] X. Chen, P. L. Zhao, and J. Zhang, “A note on ANOVA
assumptions and robust analysis for a cross-over study,”
Statistics in Medicine, vol. 21, no. 10, pp. 1377–1386, 2002.
[20] D. C. Montgomery, Design and Analysis of Experiments,J o h n
Wiley & Sons, New York, NY, USA, 4th edition, 1997.
[21] D. S. Borowitz, R. J. Grand, and P. R. Durie, “Use of pancreatic
enzyme supplements for patients with cystic ﬁbrosis in the
context of ﬁbrosing colonopathy,” Journal of Pediatrics, vol.
127, no. 5, pp. 681–684, 1995.
[22] S. Piantadosi, Clinical Trials: A Methodologic Perspective,J o h n
Wiley & Sons, New York, NY, USA, 2nd edition, 2005.
[23] J. M. Littlewood and S. P. Wolfe, “Control of malabsorption
in cystic ﬁbrosis,” Paediatric Drugs, vol. 2, no. 3, pp. 205–222,
2000.
[24] P. J. Oades, A. Bush, P. S. Ong et al., “High-strength
pancreatic enzyme supplements and large-bowel stricture inGastroenterology Research and Practice 7
cystic ﬁbrosis,” The Lancet, vol. 343, no. 8889, pp. 109–110,
1994.
[25] J. P. Freiman and S. C. FitzSimmons, “Colonic strictures in
patients with cystic ﬁbrosis: results of a survey of 114 cystic
ﬁbrosis care centers in the United States,” Journal of Pediatric
Gastroenterology and Nutrition, vol. 22, no. 2, pp. 153–156,
1996.